20.49
-0.44%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jafron Biomedical Co
Its shares trade on Shenzhen under the ticker 300529.SZ. It has been listed since 2 August 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.01bn and net income of CN¥532.8m. At that date it held total assets of CN¥5.41bn and shareholders' equity of CN¥3.47bn.
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Aug 2016
- Employees
- 3,003
- Website
- jafron.com ↗
Leadership
Pay as last reported
- Mr. Fan DongChairman of the Board, General Manager, since 2010CN¥2.8m
- Ms. Xueyun LiaoChief Financial Officer, Director, since 2023CN¥714,400
- Mr. Feng LiDeputy General Manager, Director, since 2017CN¥858,100
- Ms. Xianmin TangDeputy General Manager, Director, since 2010CN¥1.9m
- Mr. Rui WangDeputy General ManagerCN¥752,300
- Mr. Aijun WuDeputy General Manager, Chief Strategy OfficerCN¥1.8m
- Mr. Qingwu XieAssistant to President, Director, since 2023CN¥646,400
- Ms. Cong HuangSecretary of the BoardCN¥583,200
- Ms. Wen LeiDirectorCN¥180,000
- Mr. Guoqing GuoIndependent DirectorCN¥180,000
- Mr. Zhihao WenIndependent Director, since 2023CN¥180,000
- Mr. Yanjun XuIndependent DirectorCN¥180,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 68
- Environment
- 52
- Social
- 82
- Governance
- 70
- Direct emissions (scope 1)
- 8,644.93 t
- Energy emissions (scope 2)
- 10,664.54 t
- Women in the workforce
- 41.26%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 3003 full-time employees.
- Products are applied in 31 provinces and over 3000 hospitals in China.
- Engages in research, development, production, and sale of hemoperfusion products.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No details on financial performance or market share provided.
- No information on product innovation or competitive advantages.
Opportunities
- Expansion into new markets within China's healthcare sector.
- Potential growth in demand for hemoperfusion products for various medical conditions.
- Opportunity to increase market presence in the 31 provinces and 3000 hospitals.
Threats
- No specific threats mentioned in the provided information.
- No details on competition or regulatory challenges provided.
- No information on economic or industry-wide risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.